Intrahepatic CD8 T-Lymphocytes and HBV Core Expression in Relation to Response to Antiviral Therapy for Chronic Hepatitis B Patients

Journal of Medical Virology

Volumn 72, Issue 2, 2004, Pages 215-222

  Tang, Thjon J ^a   De Man, Robert A ^a   Kusters, Johannes G ^a   Kwekkeboom, Jaap ^a   Hop, Wim C J ^a   Van Der Molen, Renate G ^a   Schalm, Solko W ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antiviral therapy; CD8 T lymphocyte; Chronic hepatitis B; HBV core antigen; Response

Indexed keywords

ANTIVIRUS AGENT; CD8 ANTIGEN; HEPATITIS B CORE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RECOMBINANT ALPHA2B INTERFERON;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL; LONGITUDINAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN LOCALIZATION; T LYMPHOCYTE; TREATMENT OUTCOME;

ADOLESCENT; ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; LAMIVUDINE; LIVER; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 0345802996     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10565     Document Type: Article

References (28)

1. Bertoletti A, Chisari FV, Penna A, Guilhot S, Galati L, Missale G, Fowler P, Schlicht HJ, Vitielo A, Chesnut RC, Fiaccadori F, Ferrari C. 1993. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol 67:2376-2380.
2. Bertoletti A, Constanzo A, Chisari FV, Levrero M, Artini M, Sette A, Penna A, Giuberti T, Fiaccadori F, Ferrari C. 1994. Cytotoxic T lymphocyte response to a wild-type hepatitis B virus epitope in patients chronically infected by variants viruses carrying substitutions within the epitope. J Exp Med 180:933-943.
3. Billiau A. 1986. The mode of actions of interferons in viral infections and their possible role in the control of hepatitis B. J Hepatol 3:S171-S179.
4. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, Cavalli A, Urbani S, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. 2001. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy. Hepatology 33:963-971.
5. Chen LK, Mathieu-Mahul D, Bach FH, Dausset J, Bensussan A, Sasportes M. 1986. Recombinant interferon alpha can induce rearrangement of T cell antigen receptor alpha genes and maturation to cytotoxicity in T-lymphocytes clones in vitro. Proc Natl Acad Sci USA 83:4887-4889.
6. Chisari FV, Ferrari C. 1995. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13:29-60.
7. Chu CM, Liaw YF. 1987. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membraneous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology 92:220-225.
8. Chu CM, Liaw YF. 1992. Immunohistological study of intrahepatic expression of hepatitis B core and E antigens in chronic type B hepatitis. J Clin Pathol 45:791-795.
9. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263.
10. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, Runkel L. 1995. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182:1223-1230.
11. Griffiths GM, Mueller C. 1991. Expression of perforin and granzymes in vivo: Potential diagnostics markers for activated cytotoxic cells. Immunol Today 12:415-419.
12. Guidotti LG, Chisari FV. 1996. To kill or to cure: Options in host defence against viral infection. Curr Opin Immunol 8:478-483.
13. Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. 1983. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg vs. anti-HBe positive carriers of hepatitis B virus. Hepatology 3:656-662.
14. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Hallahan C, Park Y, Meschievitz C, Jones EA. 1988. Randomized, comtrolled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology 95:1318-1325.
15. Hsu HC, Su IJ, Lai MY, Chen DS, Chang MH, Chuang SM, Sung JL. 1987. Biologic and prognostic significance of hepatocyte hepatitis B core antigen expression in the natural course of chronic hepatitis B virus infection. J Hepatol 5:45-50.
16. Huang SN, Neurath AR. 1979. Immunohistologic demonstration of hepatitis B viral antigens in liver with reference to its significance in liver injury. Lab invest 40:1-17.
17. Kane M. 1995. Global programme for control of hepatitis B infection. Vaccine 13:S47-S49.
18. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov NV, Ferrari C, Bertoletti A. 2000. The role of virus-specific CDS(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191:1269-1280.
19. Marinos G, Naoumov NV, Williams R. 1996. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology 24:991-995.
20. Nair S, Perrillo RP. 2001. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 34:1021-1026.
21. Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht HJ, Vitiello A, Chesnut R, Person JL, Redeker AG, Chisari FV. 1993. HLA A2 restricted cytotoxic T-lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 150:4659-4671.
22. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Jr., Lindsay K, Payne J, Dienstag JL, O'Brien C, Tamburro C, Jacobson IM. 1990. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 323:295-301.
23. Peters M. 1989. Mechanisms of action of interferons. Semin Liver Dis 9:235-239.
24. Rehermann B. 2000. Intrahepatic T-cells in hepatitis B: Viral control versus liver cell injury. J Exp Med 191:1263-1268.
25. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, Moss B, Sette A, Chisari FV. 1995. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181:1047-1058.
26. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. 1996. The hepatitis B virus persists for decades after patient's recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104-1108.
27. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, Brown D, Amlot PL, Williams R, Vergani D, Dusheiko GM, Bertoletti A. 2000. Incubation phase of acute hepatitis B in man: Dynamic of cellular immune mechanisms. Hepatology 32:1117-1124.
28. Yoo JY, Howard R, Waggoner JG, Hoofnagle JH. 1987. Peroxidase-antiperoxidase detection of hepatitis B surface and core antigen in liver biopsy specimens from patients with chronic type B hepatitis. J Med Virol 23:273-281.